Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
The IgG Clock: Redose Using IgG Kinetics
When to Begin FcRn: Initiation Criteria, Key Evidence
The 2-Point Signal: Apply ≥2-Point Rule
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Target Locked in gMG: Why T2T Matters
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
April 13, 2026
Pittsburgh, Pennsylvania
Minimal By Design: Define MSE Endpoints
Shared Goals, Shared Gains: Align With Patient Preferences
April 13, 2026 Pittsburgh, Pennsylvania
12:00 PM - 01:00 PM ET
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
David Staskin, MD
Matt T. Rosenberg, MD
Kennedy Koebbe, MSN, RN
Emerging Evidence: IgAN Disease-Modifying Agents
Richard Lafayette, MD, FACP
Hong Zhang
Turning Flares Into Function: Flag Uncontrolled Disease
Escalate With Intention: Stepwise, Target-Anchored Moves
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
Emerging Therapies in IgAN: Who Could Benefit the Most?
APRIL Uncovered: An Upstream Driver in IgAN
Dana Rizk, MD
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
Suzuki Yusuke, MD, PhD
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
María-Victoria Mateos, MD, PhD
Luciano Costa, M.D., Ph.D.
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Cristina Rodriguez, MD
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
Kathryn Arbour
Eileen M. O'Reilly, MD
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.